查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598386

治療性卡介苗疫苗市場：按類型、人口統計和最終用戶分類 - 全球預測 2025-2030

Therapeutic BCG Vaccine Market by Type (Immune BCG, Therapy BCG), Demographics (Adults, Pediatrics), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年治療性卡介苗疫苗市值為5,776萬美元，預計2024年將達到6,031萬美元，複合年成長率為4.50%，預計到2030年將達到7,863萬美元。

治療性卡介苗疫苗最初是為結核病開發的，但也已用於治療非肌肉層浸潤性膀胱癌（NMIBC）並提供針對多種疾病的免疫力，包括糖尿病和其他癌症，其範圍正在擴大，包括探索其潛力。卡介苗疫苗的需求源於其免疫調節特性，這可能會增強免疫系統瞄準和破壞癌細胞的能力。卡介苗疫苗在膀胱癌免疫治療中的應用已有充分記錄，新的研究顯示其在腫瘤學和自體免疫疾病方面有更廣泛的應用。最終用途範圍主要包括醫院、癌症治療中心和尋求創新治療方法的研究機構。影響市場成長的關鍵因素包括癌症發病率上升、正在進行的研究證實廣泛的治療應用以及醫療保健投資的增加。相反，副作用風險、嚴格的監管要求以及新興市場認知度低等挑戰構成了障礙。隨著研究進展將應用擴展到其他癌症類型和慢性疾病，市場機會就出現了。投資宣傳宣傳活動並利用與研究機構的夥伴關係關係可以為您帶來競爭優勢。限制包括 BCG 生產和分銷物流的複雜性以及對強大基礎設施的需求。需要創新的領域包括開發更複雜的製劑以提高療效並減少副作用，以及卡介苗與新藥物傳輸技術的整合。市場的性質正在轉向精準醫療，重點是客製化治療解決方案。與生物技術公司的持續研究和合作可能會促進進一步的突破。此外，加強對醫療保健專業人員有關卡介苗疫苗擴大治療用途的教育也可能加速市場採用和成長。

主要市場統計
基準年[2023] 5776萬美元
預計年份 [2024] 6031萬美元
預測年份 [2030] 7863萬美元
複合年成長率（%） 4.50%

市場動態：揭示快速發展的治療性卡介苗疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變治療性卡介苗市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 嬰幼兒人口的增加與兒科醫療的發展
    • 高投入研發治療性卡介苗疫苗
    • 透過疫苗宣傳活動提高認知
  • 市場限制因素
    • 缺乏治療性卡介苗疫苗
  • 市場機會
    • 開發中國家和低度開發國家開拓的市場
    • 聯合國加大力度預防結核病
  • 市場挑戰
    • 卡介苗疫苗相關的副作用

波特五力：駕馭治療性卡介苗疫苗市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解治療性卡介苗疫苗市場的外部影響

外部宏觀環境因素在塑造治療性卡介苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解治療性卡介苗市場的競爭狀況

治療性卡介苗疫苗市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣治療性 BCG 疫苗市場供應商績效評估

FPNV 定位矩陣是評估治療性 BCG 疫苗市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製治療性 BCG 疫苗市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，治療性卡介苗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 嬰兒人口的增加和兒科醫療的進步
      • 大量投資治療性卡介苗疫苗的研發
      • 透過疫苗宣傳活動提高認知
    • 抑制因素
      • 治療性卡介苗疫苗短缺
    • 機會
      • 開發中國家和最不開發中國家開拓的市場
      • 擴大聯合國預防結核病的努力
    • 任務
      • 卡介苗疫苗相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章治療性卡介苗疫苗市場：依類型

  • 免疫卡介苗
  • 卡介苗治療

第7章依人口統計的治療性卡介苗疫苗市場

  • 成人
  • 小兒科

第8章治療性 BCG 疫苗市場：依最終用戶分類

  • 診所
  • 醫院

第9章美洲治療性卡介苗疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區治療性卡介苗疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲治療性卡介苗疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AJ Vaccines A/S
  • Bharat Biotech Ltd.
  • Biomed-Lublin SA
  • China National Biotec Group Company Limited
  • Green Signal Bio Pharma Private Limited
  • InterVax Ltd.
  • Japan BCG Laboratory
  • Merck & Co., Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Statens Serum Institut
  • Taj Pharmaceuticals Limited
  • Torlak Institute of Virology
Product Code: MRR-030298DFF712

The Therapeutic BCG Vaccine Market was valued at USD 57.76 million in 2023, expected to reach USD 60.31 million in 2024, and is projected to grow at a CAGR of 4.50%, to USD 78.63 million by 2030.

The therapeutic BCG vaccine, originally developed for tuberculosis, has expanded in scope to include its application in treating non-muscle invasive bladder cancer (NMIBC) and exploring potential roles in modulating the immune response for various diseases, including some forms of diabetes and other cancers. The necessity of the BCG vaccine stems from its immunomodulatory properties, which can potentially enhance the immune system's ability to target and destroy cancer cells, making it vital in cancer treatment where immunotherapy is relevant. Its application in immunotherapy for bladder cancer has been well-documented, and emerging research suggests broader applications in oncology and auto-immune conditions. The end-use scope primarily involves hospitals, cancer treatment centers, and research institutions seeking innovative treatment approaches. Key factors influencing market growth include increasing cancer prevalence, ongoing research substantiating broader therapeutic uses, and rising healthcare investments. Conversely, challenges such as the risk of side effects, stringent regulatory requirements, and limited awareness in emerging markets pose barriers. Market opportunities lie in expanding its application to other cancer types and chronic diseases, driven by advancements in research. Investing in awareness campaigns and leveraging partnerships with research institutions could provide a competitive edge. Limitations include the complexity of BCG production and distribution logistics, which require robust infrastructure. Areas ripe for innovation include developing more refined formulations to enhance efficacy and reduce side effects, as well as integrating BCG with new drug delivery technologies. The nature of the market is transitioning towards precision medicine, emphasizing tailored therapeutic solutions. Continuous research and collaboration with biotech firms could spur further breakthroughs. Enhancing education among healthcare professionals regarding the BCG vaccine's expanded therapeutic uses could also accelerate market adoption and growth.

KEY MARKET STATISTICS
Base Year [2023] USD 57.76 million
Estimated Year [2024] USD 60.31 million
Forecast Year [2030] USD 78.63 million
CAGR (%) 4.50%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Therapeutic BCG Vaccine Market

The Therapeutic BCG Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising infant population and growing advancement in the pediatric care
    • High investment in research & development of therapeutic BCG vaccine
    • Increasing awareness through vaccination campaign
  • Market Restraints
    • Lack of therapeutic BCG vaccine
  • Market Opportunities
    • Untapped market in developing and underdeveloped countries
    • Growing initiatives by United Nations (UN) for TB preventions
  • Market Challenges
    • Side effects associated with BCG vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Therapeutic BCG Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Therapeutic BCG Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Therapeutic BCG Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Therapeutic BCG Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Therapeutic BCG Vaccine Market

A detailed market share analysis in the Therapeutic BCG Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Therapeutic BCG Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Therapeutic BCG Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Therapeutic BCG Vaccine Market

A strategic analysis of the Therapeutic BCG Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic BCG Vaccine Market, highlighting leading vendors and their innovative profiles. These include AJ Vaccines A/S, Bharat Biotech Ltd., Biomed-Lublin S.A., China National Biotec Group Company Limited, Green Signal Bio Pharma Private Limited, InterVax Ltd., Japan BCG Laboratory, Merck & Co., Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Statens Serum Institut, Taj Pharmaceuticals Limited, and Torlak Institute of Virology.

Market Segmentation & Coverage

This research report categorizes the Therapeutic BCG Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Immune BCG and Therapy BCG.
  • Based on Demographics, market is studied across Adults and Pediatrics.
  • Based on End User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising infant population and growing advancement in the pediatric care
      • 5.1.1.2. High investment in research & development of therapeutic BCG vaccine
      • 5.1.1.3. Increasing awareness through vaccination campaign
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of therapeutic BCG vaccine
    • 5.1.3. Opportunities
      • 5.1.3.1. Untapped market in developing and underdeveloped countries
      • 5.1.3.2. Growing initiatives by United Nations (UN) for TB preventions
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with BCG vaccine
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Therapeutic BCG Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Immune BCG
  • 6.3. Therapy BCG

7. Therapeutic BCG Vaccine Market, by Demographics

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Pediatrics

8. Therapeutic BCG Vaccine Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Americas Therapeutic BCG Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Therapeutic BCG Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Therapeutic BCG Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AJ Vaccines A/S
  • 2. Bharat Biotech Ltd.
  • 3. Biomed-Lublin S.A.
  • 4. China National Biotec Group Company Limited
  • 5. Green Signal Bio Pharma Private Limited
  • 6. InterVax Ltd.
  • 7. Japan BCG Laboratory
  • 8. Merck & Co., Inc.
  • 9. Sanofi S.A.
  • 10. Serum Institute of India Pvt. Ltd.
  • 11. Statens Serum Institut
  • 12. Taj Pharmaceuticals Limited
  • 13. Torlak Institute of Virology

LIST OF FIGURES

  • FIGURE 1. THERAPEUTIC BCG VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. THERAPEUTIC BCG VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. THERAPEUTIC BCG VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. THERAPEUTIC BCG VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THERAPEUTIC BCG VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THERAPEUTIC BCG VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY IMMUNE BCG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY THERAPY BCG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. THERAPEUTIC BCG VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. THERAPEUTIC BCG VACCINE MARKET, FPNV POSITIONING MATRIX, 2023